Skip to main content
SpringerLink
Log in

Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

  • Letter to the Editor
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

The Original Article was published on 23 February 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Braillon A, Taiebi F, Bernoussi A. Nalmefene phase IV study: a seeding flying in the face of evidence? Clin Drug Investig. 2018. https://doi.org/10.1007/s40261-018-0628-2.

    PubMed  Google Scholar 

  2. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73:706–13.

    Article  CAS  PubMed  Google Scholar 

  3. Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23:1432–42.

    Article  CAS  PubMed  Google Scholar 

  4. van den Brink W, Sørensen P, Torup L, Mann K, Gual A, SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28:733–44.

    Article  PubMed  Google Scholar 

  5. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12:e1001924.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta- analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2017. https://doi.org/10.1111/add.13974 (Online 80 Sep 20).

    PubMed  Google Scholar 

  7. Roerecke M, Gual A, Rehm J. Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses. Clin Psychiatry. 2013;74(12):e1181–9. https://doi.org/10.4088/JCP.13r08379.

    Article  Google Scholar 

  8. Rahhali N, Millier A, Briquet B, Laramée P, Aballéa S, Toumi M, François C, Rehm J, Daeppen JB. Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data. BMC Public Health. 2015;21(15):1271. https://doi.org/10.1186/s12889-015-2606-4.

    Article  Google Scholar 

  9. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108–20. https://doi.org/10.1016/S2468-2667(17)30003-8 (Epub 2017 Feb 7).

    Article  PubMed  Google Scholar 

  10. Rehm J, Marmet S, Anderson P, Gual A, Kraus L, Nutt DJ, Room R, Samokhvalov AV, Scafato E, Trapencieris M, Wiers RW, Gmel G. Defining substance use disorders: do we really need more than heavy use? Alcohol Alcohol. 2013;48(6):633–40. https://doi.org/10.1093/alcalc/agt127 (Epub 2013 Aug 7. Review).

    Article  CAS  PubMed  Google Scholar 

  11. Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use disorders. JAMA. 2014;311(18):1861–2. https://doi.org/10.1001/jama.2014.3629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Luquiens A, Reynaud M, Aubin HJ. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011;46(5):586–91.

    Article  CAS  PubMed  Google Scholar 

  13. Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat. 2007;33(1):71–80.

    Article  PubMed  Google Scholar 

  14. Gottheil E, Thornton CC, Skoloda TE, Alterman AI. Follow-up of abstinent and nonabstinent alcoholics. Am J Psychiatry. 1982;139(5):560–5.

    Article  CAS  PubMed  Google Scholar 

  15. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf. Accessed Jan 2018.

  16. Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679–85. https://doi.org/10.1176/appi.ps.201000553.

    Article  PubMed  Google Scholar 

  17. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–9. https://doi.org/10.1016/j.drugalcdep.2008.07.018 (Epub 2008 Sep 25).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Roselló 161 Bajos, 08036, Barcelona, Spain

    Pablo Barrio, Lluisa Ortega & Antoni Gual

  2. Addictive Behavior Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Josep Guardia

  3. Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain

    Carlos Roncero

  4. Institute of Biomedicine of Salamanca, University of Salamanca, Salamanca, Spain

    Carlos Roncero

  5. Addictive Behaviors Unit, Germanes Hospitalàries, Sant Boi, Barcelona, Spain

    Lara Yuguero

Authors
  1. Pablo Barrio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lluisa Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josep Guardia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Roncero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lara Yuguero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antoni Gual
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Barrio.

Ethics declarations

Funding

No funding was received to prepare this letter.

Conflict of interest

Dr. Barrio, Dr. Roncero, Dr. Guardia and Dr. Gual have received honoraria from Lundbeck. Dr. Barrio has also received honoraria from Pfizer. Dr. Roncero has also received honoraria from Janssen-Cilag, Otsuka, Server, GSK, Rovi, Astra, MSD and Sanofi. Dr. Yuguero and Dr. Ortega have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barrio, P., Ortega, L., Guardia, J. et al. Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?. Clin Drug Investig 38, 387–388 (2018). https://doi.org/10.1007/s40261-018-0625-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0625-5

Search

Navigation